Related Experiment Video
Updated: Jul 19, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Review of real-world experience with lurbinectedin in relapsed/refractory small cell lung cancer
Mustafa Wasifuddin1, Nosakhare Paul Ilerhunmwuwa1, Henry Becerra1
1Department of Internal Medicine, One Brooklyn Health/Brookdale University Hospital and Medical Center, Brooklyn, New York, USA.
Abstract:
Lurbinectedin, a novel antineoplastic agent, was granted the orphan drug designation by the United States Food and Drug Administration (US FDA) and approved for use in relapsed/refractory small cell lung cancer in June 2020. The approval was granted after its efficacy was demonstrated in a multicenter open-label, multi-cohort study enrolling 105 participants. Since then, real-world studies have examined the efficacy and safety profiles of lurbinectedin in clinical practice. By examining these outcomes, this review aims to provide clinicians with the tools necessary to make informed clinical decisions.
Insights
Lurbinectedin is an orphan drug approved for relapsed/refractory small cell lung cancer. This review examines real-world studies on its efficacy and safety to aid clinical decision-making.
Area of Science:
- Oncology
- Pharmacology
Background:
- Lurbinectedin, an antineoplastic agent, received orphan drug designation from the US FDA.
- It was approved in June 2020 for relapsed/refractory small cell lung cancer (SCLC).
- Initial approval was based on a multicenter study of 105 participants.
Purpose of the Study:
- To review real-world studies on lurbinectedin's efficacy and safety in clinical practice.
- To provide clinicians with data for informed treatment decisions regarding lurbinectedin.
- To consolidate current understanding of lurbinectedin's performance in routine care.
Main Methods:
- Systematic review of published real-world evidence on lurbinectedin.
- Analysis of efficacy and safety data from clinical practice studies.
- Synthesis of outcomes to assess lurbinectedin's utility in relapsed/refractory SCLC.
Main Results:
- Real-world studies are evaluating lurbinectedin's effectiveness and tolerability.
- Observed outcomes in clinical practice are being compared to trial data.
- Safety profiles in diverse patient populations are under scrutiny.
Conclusions:
- Real-world data are crucial for understanding lurbinectedin's role in SCLC treatment.
- This review synthesizes evidence to support clinical application of lurbinectedin.
- Informed decisions regarding lurbinectedin can be made based on compiled clinical outcomes.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
06:25Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
Published on: March 29, 2024
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers